Introduction：Basic information about CAS 160707-69-7|Apricitabine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Apricitabine |
|---|
| CAS Number | 160707-69-7 | Molecular Weight | 229.256 |
|---|
| Density | 1.7±0.1 g/cm3 | Boiling Point | 475.4±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C8H11N3O3S | Melting Point | / |
|---|
| MSDS | / | Flash Point | 241.3±31.5 °C |
|---|
Names
| Name | 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one |
|---|
| Synonym | More Synonyms |
|---|
Apricitabine BiologicalActivity
| Description | Apricitabine (SPD754; AVX754), the (-) enantiomer of 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC), is a highly selective and orally active HIV-1 reverse transcriptase (RT) inhibitor (Ki=0.08 μM), as well as inhibits DNA polymerases α, β, and γ with Ki value of 300 μM, 12 μM, and 112.25 μM, respectively[1]. Apricitabine (SPD754; AVX754) shows promising antiretroviral efficacy, good tolerability and a low propensity for resistance selection in antiretroviral-naive HIV infection[2]. |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>HIVResearch Areas >>InfectionSignaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogSignaling Pathways >>Cell Cycle/DNA Damage >>DNA/RNA Synthesis |
|---|
| Target | HIV-1 |
|---|
| In Vitro | Apricitabine (SPD754; AVX754) is against clinical isolates of HIV-1 in cultured PBMCs with IC50 values of 0.2 μM, 1.45 μM, 2.2 μM and 2.4 μM for HIV-1RF, Wild type, 3TC resistant, 3TC and AZT resistant, respectively[1]. Apricitabine (SPD754; AVX754) has antiviral activities agsinst HIV-1 clinical isolates resistant to nucleoside reverse transcriptase inhibitors in MT-4 cells, exhibits Mean IC50 values of 20 μM, 25 μM, 30 μM,21 μM,55 μM,32 μM and 71 μM for HIV-1IIIB,Wild-type (control), Zidovudine-resistant, Lamivudine-resistant, Zidovudine-resistant/lamivudine-resistant, Abacavir-resistant and Stavudine-resistant viruses,respectively[2]. |
|---|
| In Vivo | Apricitabine (SPD754; AVX754) (oral adminstation; 10 mg/kg; once a day) exhibits a good oral bioavailability of 68% for males and 69.4% for females rats. And the T1/2, AUC0–∞, Tmax, Cmax are 62.2 mins, 157.4 μg/min/ml and 37.3 mins, 1.16 μg/ml in female rats[1]. Apricitabine (SPD754; AVX754) (intravenous injection; 10 mg/kg; once a day) exhibits the T1/2, AUC0–∞ values of 12.7 mins, 226.9 μg/min/ml in female rats[1]. |
|---|
| References | [1]. de Muys JM, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.Antimicrob Agents Chemother. 1999 Aug;43(8):1835-44. [2]. Cahn P, et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.AIDS. 2006 Jun 12;20(9):1261-8. |
|---|
Chemical & Physical Properties
| Density | 1.7±0.1 g/cm3 |
|---|
| Boiling Point | 475.4±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C8H11N3O3S |
|---|
| Molecular Weight | 229.256 |
|---|
| Flash Point | 241.3±31.5 °C |
|---|
| Exact Mass | 229.052109 |
|---|
| PSA | 115.67000 |
|---|
| LogP | -1.35 |
|---|
| Vapour Pressure | 0.0±2.7 mmHg at 25°C |
|---|
| Index of Refraction | 1.755 |
|---|
| InChIKey | RYMCFYKJDVMSIR-RNFRBKRXSA-N |
|---|
| SMILES | Nc1ccn(C2COC(CO)S2)c(=O)n1 |
|---|
Synonyms
| 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2(1H)-one |
| SPD754 |
| AVX754 |
| 4-Amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]-2(1H)-pyrimidinone |
| 2(1H)-Pyrimidinone, 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]- |
| Apricitabine |
